Celldex prices upsized $250M public offering at $42/share; net proceeds ~$234.8M

Celldex Therapeutics, Inc.

Celldex priced 5,952,381 shares at $42.00 per share in an upsized public offering for $250M gross proceeds.
Expected net proceeds of ~$234.8M after underwriting discounts and estimated expenses.
Proceeds to fund clinical development of CDX-0159 and other pipeline candidates, and bispecific antibody platform.
Underwriters have 30-day option to purchase up to 892,857 additional shares at the same price.
Offering expected to close July 16, 2021; joint book-runners: Jefferies, SVB Leerink, Guggenheim, Cantor.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.